What is capecitabine Xeloda? How does capecitabine work? When is capecitabine prescribed?
Treatment given to shrink or eliminate a tumor before surgery is called neoadjuvant therapy. In some patients with breast cancer treated with neoadjuvant chemotherapy, residual invasive cancer can be detected in breast tissue samples and lymph nodes removed during surgery. These patients tend to have worse long-term outcomes compared with women who respond completely to neoadjuvant therapy.
It has not been determined which patients can have long-term survival with treatment. Metastatic site, number of disease sites, prior chemotherapeutic regimens and human epidermal growth factor receptor-2 HER2 status did not differ between the two groups. The proportion of patients who received metronomic regimens was significantly higher in long-term survivors than in non-long-term survivors
OncologyPRO, in partnership with medwireNews, brings you updates each day in the field of medical oncology. Watch leading oncology experts sharing knowledge in ESMO educational videos or reporting on recent study results presentation. Haven't had much time lately?
The present study was undertaken to determine the relationship between tumor response to neoadjuvant chemotherapy including capecitabine and long-term treatment outcomes in patients with operable breast cancer. Long-term treatment outcomes and metastasis-free survival rates were evaluated using the Kaplan-Meier method. Such factors as the primary tumor size, regional tumor spread, receptor status of tumor tissue and the number of chemotherapy courses were found to have no impact on the frequency of hematogenous metastasis.
Colleague's E-mail is Invalid. Your message has been successfully sent to your colleague. Save my selection.
Skip to Content. Use the menu to see other pages. This section explains the types of treatments that are the standard of care for early-stage and locally advanced breast cancer.
Capecitabine is an important drug in the therapeutic armamentarium for metastatic breast cancer. On the basis of data demonstrating consistent activity across several trials in patients with heavily pretreated breast cancer, capecitabine was approved in the U. Capecitabine plus docetaxel XT was approved by the U.
Outcomes remained significantly better for older patients with early breast cancer who were treated with standard chemotherapy rather than capecitabine Xelodalong-term findings of the CALGB trial indicated. At This despite the fact that the adjuvant chemotherapy regimens used during the trial are now considered inferior to today's regimens for both younger and older patients, they wrote in the Journal of Clinical Oncology.